Fananserin

Drug Profile

Fananserin

Alternative Names: RP 62203

Latest Information Update: 26 Jun 2002

Price : $50

At a glance

  • Originator Aventis
  • Class Cyclic S oxides; Naphthalenes; Small molecules
  • Mechanism of Action Dopamine D4 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alcoholism; Anxiety disorders; Eating disorders; Major depressive disorder; Migraine; Sleep disorders
  • Discontinued Schizophrenia

Most Recent Events

  • 26 Jun 2002 No development reported - Phase-II for Depression in USA (PO)
  • 26 Jun 2002 No development reported - Phase-II for Depression in France (PO)
  • 26 Jun 2002 No development reported - Phase-II for Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top